Despite a few contradictory studies that report that BTZ can reduce the expression of Pgp [11], the majority of the evidence reports the overexpression of the transmembrane protein Pgp in myeloma patients and points to it as one of the major factors regulating acquired resistance to BTZ [11]. The gene discussed is CASC3; the disease is plasma cell myeloma.